This Month in Psychopharmacology

FDA Approves Dexmedetomidine Sublingual Film for At-Home Treatment of Acute Agitation

The U.S. Food and Drug Administration (FDA) has approved dexmedetomidine sublingual film (IGALMI®) for at-home treatment of acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults. This marks the first FDA-approved treatment specifically indicated for self-administration at home during episodes of acute agitation associated with these conditions.


Dexmedetomidine is a highly selective α2-adrenergic receptor agonist that was previously approved in 2022 for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults under the supervision of a healthcare provider. The expanded approval allows patients to self-administer the medication outside healthcare settings. The film can be administered sublingually (under the tongue) or buccally (between the lower lip and gum), potentially enabling earlier intervention during episodes of acute agitation.


The approval was supported by the phase 3 SERENITY At-Home trial (SERENITY III; NCT05658510), a randomized, double-blind, placebo-controlled, 12-week study evaluating the safety and tolerability of self-administered dexmedetomidine sublingual film in adults experiencing agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder. During the study, 1,160 agitation episodes in 102 patients were treated with dexmedetomidine. The trial met its primary endpoint of safety and tolerability, with a consistent tolerability profile observed across repeated administrations during the 12-week study period.


The most commonly reported adverse events (≥5% and more frequent than placebo) included somnolence, dry mouth, dizziness, and oral paresthesia or hypoesthesia. No patients discontinued treatment because of tolerability issues. Important safety considerations include the potential for hypotension, orthostatic hypotension, and bradycardia.


The efficacy of dexmedetomidine sublingual film for acute agitation was previously established in the phase 3 SERENITY I and SERENITY II trials, which were randomized, double-blind, placebo-controlled studies conducted in supervised healthcare settings. Both trials demonstrated statistically significant improvements in agitation, assessed using the Positive and Negative Syndrome Scale–Excited Component (PEC), compared with placebo. Across the studies, dexmedetomidine was associated with an average reduction of approximately 9.6 points in PEC total score at 2 hours after administration, compared with approximately 4.9 points with placebo. Treatment effects were observed as early as 20 minutes after administration with some studied doses.


The expanded approval provides a noninjectable treatment option for managing acute agitation outside supervised healthcare settings. While the earlier SERENITY I and II trials established efficacy in supervised settings, the SERENITY At-Home trial provided additional safety and tolerability data supporting self-administration.


Mechanism of Action

  • Dexmedetomidine is a highly selective α2-adrenergic receptor agonist.
  • Its effects on acute agitation are thought to result from activation of presynaptic α2-adrenergic receptors.
  • Activation of these receptors inhibits norepinephrine release, reducing central noradrenergic signaling and sympathetic nervous system activity.

» Teva Pharmaceuticals Press Release


Additional Education and Practice Resources

Image

Clinical Case Study
78-Year-Old Man With Visual Hallucinations and Agitation
CME/CE Credit: 0.50 | Expires: November 3, 2028

 NEI Clinical Toolkit

NEI Clinical Toolkit
Screening and Diagnosis: Functioning and Quality of Life

Image

Patient Education
Health Behavior Guides: Improving Your Adherence
Educational patient handout!

References:

1. IGALMI® (dexmedetomidine) sublingual film. Prescribing information. Teva Neuroscience, Inc; 2026.
2. ClinicalTrials.gov. SERENITY III (SERENITY At-Home). NCT05658510.
3. Teva Pharmaceuticals. U.S. FDA approves IGALMI as first at-home acute treatment for agitation associated with schizophrenia, schizoaffective disorder, or bipolar disorder. November 16, 2026.